Oncotelic Therapeutics (OTCQB: OTLC), through its wholly owned subsidiary Pet2DAO, Inc., has opened registration for BIO REBOOT, an initiative powered by its PDAOAI artificial intelligence drug discovery platform. The program invites scientists, AI developers, and biotech founders to contribute research questions, technical expertise, and drug discovery ideas to the PDAOAI community. Selected projects may be considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning, and clinical development. This move matters because it lowers barriers to entry for early-stage innovators and could accelerate the translation of AI-driven hypotheses into viable therapies, particularly for cancers with high unmet need.
Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study demonstrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations underscore the platform's potential to mine vast scientific literature and identify novel biomarkers, a critical step in precision oncology.
The implications are significant for investors and the biotech sector. By inviting external participation, Oncotelic is effectively crowdsourcing innovation while retaining rights to support promising projects, creating a pipeline of future assets. The PDAOAI platform, which supports Oncotelic's own oncology and immunotherapy work, could become a revenue-generating hub if it attracts enough high-quality projects. For a company focused on rare pediatric indications and cancers with substantial unmet needs, this approach may yield diversified opportunities beyond its internal pipeline.
For those seeking the full details, the complete press release is available at https://ibn.fm/dxB7y. The latest news and updates relating to OTLC can be found in the company's newsroom at https://ibn.fm/OTLC. BioMedWire, a specialized communications platform for the biotechnology, biomedical sciences, and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire and see the full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.
Oncotelic's dual announcement positions it at the intersection of AI and drug discovery, a space attracting increasing attention and investment. If BIO REBOOT succeeds in generating a robust pipeline of funded projects, it could validate the PDAOAI model and create a new template for virtual drug development. The conference presentations will offer early evidence of the platform's capabilities, potentially attracting partners and investors. For a small-cap company like Oncotelic, such initiatives could enhance visibility and credibility in a competitive landscape. As the biotech industry continues to embrace AI, Oncotelic's proactive community-building and public demonstrations may serve as a catalyst for broader adoption and collaboration.
